Sunday, July 17, 2016

BRIEF-Genentech says phase III study evaluating Gazyva did not meet primary endpoint

* Genentech provides update on phase III study of Gazyva in

people with previously untreated diffuse large b-cell lymphoma

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)